Key facts
- Perseo Pharma’s last known valuation is $2.6M (May 2020).
- It has raised $410K; the latest was Later Stage VC in Aug 2025.
- Notable investors include 7G Bioventures, BioBac, Business Angels Switzerland.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Perseo Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Perseo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Perseo Pharma
Developer of an enzyme therapeutics platform designed to treat digestive diseases. The company's platform uses proprietary nanotechnology to offer oral enzyme therapies to protect the enzyme in a nano-shield and bind it specifically to the mucus of the small intestine, where the digestion takes place, enabling patients to eliminate the pill burden to be consumed.
- Sector
- Healthcare
- HQ
- Muttenz, Switzerland
- Founded
- 2019
- Employees
- 9
- Website
- perseo-pharma.com/
- Ownership
- Privately Held (backing)
Perseo Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Perseo Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Perseo Pharma in its N-PORT filings yet. We sweep new filings monthly.